4//SEC Filing
BRATTON DOUGLAS K 4
Accession 0000899243-20-022430
CIK 0001714899other
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 4:50 PM ET
Size
16.2 KB
Accession
0000899243-20-022430
Insider Transaction Report
Form 4
BRATTON DOUGLAS K
10% Owner
Transactions
- Sale
Common Stock
2020-08-12$31.65/sh−1,443,247$45,678,768→ 12,201,634 total(indirect: By AKDL, L.P.)
Holdings
- 448,035(indirect: By Neuro Line Partners, L.P.)
Common Stock
AKDL, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-08-12$31.65/sh−1,443,247$45,678,768→ 12,201,634 total(indirect: By AKDL, L.P.)
Holdings
- 448,035(indirect: By Neuro Line Partners, L.P.)
Common Stock
Crestline SI (GP), L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-08-12$31.65/sh−1,443,247$45,678,768→ 12,201,634 total(indirect: By AKDL, L.P.)
Holdings
- 448,035(indirect: By Neuro Line Partners, L.P.)
Common Stock
Crestline Investors, Inc.
10% Owner
Transactions
- Sale
Common Stock
2020-08-12$31.65/sh−1,443,247$45,678,768→ 12,201,634 total(indirect: By AKDL, L.P.)
Holdings
- 448,035(indirect: By Neuro Line Partners, L.P.)
Common Stock
Crestline Management, LP
10% Owner
Transactions
- Sale
Common Stock
2020-08-12$31.65/sh−1,443,247$45,678,768→ 12,201,634 total(indirect: By AKDL, L.P.)
Holdings
- 448,035(indirect: By Neuro Line Partners, L.P.)
Common Stock
Footnotes (4)
- [F1]These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.
- [F2](Continued from footnote 1) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
- [F3]These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.
- [F4](Continued from footnote 3) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
Issuer
Denali Therapeutics Inc.
CIK 0001714899
Entity typeother
Related Parties
1- filerCIK 0001281933
Filing Metadata
- Form type
- 4
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 4:50 PM ET
- Size
- 16.2 KB